Insulin-Like Growth Factor-1 at Diagnosis and during Subsequent Years in Adolescents with Type 1 Diabetes

Figure 1

(a) Glycaemic control by HbA1C (%); (b) C-peptide (nmol/l); (c) IGF-1 (μg/l); and (d) insulin dose (U/kg) at diagnosis and 3, 9, 18, and 48 months after diagnosis and treatment with multiple insulin injection regimes (mean ± SD). and in comparison to diabetes onset; in comparison to 3 months.

(a)

(b)

(c)

(d)